Graham Capital Management L.P. Increases Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Graham Capital Management L.P. lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 610.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 30,956 shares of the company's stock after purchasing an additional 26,596 shares during the quarter. Graham Capital Management L.P. owned about 0.09% of TransMedics Group worth $1,930,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. FORA Capital LLC acquired a new position in shares of TransMedics Group during the 4th quarter worth $1,788,000. Frontier Capital Management Co. LLC acquired a new position in shares of TransMedics Group during the 4th quarter worth $9,415,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of TransMedics Group by 40.1% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 7,290 shares of the company's stock worth $455,000 after purchasing an additional 2,086 shares during the period. Divisadero Street Capital Management LP grew its stake in shares of TransMedics Group by 312.8% during the 4th quarter. Divisadero Street Capital Management LP now owns 158,480 shares of the company's stock worth $9,881,000 after purchasing an additional 120,090 shares during the period. Finally, Cetera Investment Advisers grew its stake in shares of TransMedics Group by 8.3% during the 4th quarter. Cetera Investment Advisers now owns 8,260 shares of the company's stock worth $515,000 after purchasing an additional 634 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares of the company's stock, valued at $84,641.16. This trade represents a 89.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 7.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TMDX. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Piper Sandler reaffirmed an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Oppenheimer increased their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, TransMedics Group has an average rating of "Moderate Buy" and an average price target of $126.70.

TransMedics Group Price Performance

NASDAQ TMDX traded down $0.23 during trading hours on Friday, reaching $121.58. The company's stock had a trading volume of 966,002 shares, compared to its average volume of 1,360,025. The stock has a market cap of $4.11 billion, a PE ratio of 129.34 and a beta of 1.91. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company's 50-day moving average is $83.99 and its two-hundred day moving average is $75.86. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. During the same period last year, the company earned $0.35 EPS. The firm's revenue for the quarter was up 48.2% compared to the same quarter last year. Analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.